Zometa
Zometa, or zoledronate, is a bisphosphonate drug marketed by Novartis taken
intravenously and used to prevent osteoporosis and skeletal fractures in
patients with multiple myeloma and other cancers. Multiple myeloma patients
taking Zometa have been shown to have a high incidence of osteonecrosis of the
jaw. Osteonecrosis, or "bone death," of the jaw is a condition in which there
is pain, swelling, and bone damage around the tooth sockets. Loss of bone can
lead to loose teeth, bone spurs, and other problems. Most cases of
osteonecrosis of the jaw occur following dental procedures, and are often
complicated by infection.
<< back
The information you obtain at this site is not, nor is it intended to be, legal advice. You should consult an attorney for individual advice regarding your own situation.
